IHC - BHCG

IHC – β-hCG Test

The IHC β-hCG (Beta Human Chorionic Gonadotropin) Test is a specialized immunohistochemistry (IHC) diagnostic test used to detect β-hCG protein expression in tissue samples. This test is widely used in pathology for diagnosing germ cell tumors, trophoblastic tumors, choriocarcinoma, certain testicular cancers, ovarian tumors, and other hCG-producing malignancies.

β-hCG is a hormone commonly produced during pregnancy. However, abnormal β-hCG expression can also occur in certain tumors, making it an important tumor marker for tissue diagnosis and cancer classification.

The IHC β-hCG test is usually performed on FFPE (Formalin-Fixed Paraffin-Embedded) tissue biopsy samples using advanced antibody staining techniques. Expert pathologists examine stained tissue microscopically to identify β-hCG protein expression and determine tumor characteristics.

This test is particularly valuable when routine histopathology findings are inconclusive or when differentiating between specific tumor subtypes is essential for accurate diagnosis.

Identifying β-hCG positivity helps oncologists confirm tumor origin, classify malignancy type, assess prognosis, and guide personalized treatment planning.

Benefits of the Test

• Detects β-hCG-producing tumors accurately
• Supports tumor classification
• Helps diagnose germ cell and trophoblastic tumors
• Assists cancer subtype differentiation
• Supports personalized treatment planning
• Improves pathology diagnosis confidence

Why Doctors Recommend This Test

Doctors commonly recommend the β-hCG IHC Test when:

• Germ cell tumor is suspected
• Choriocarcinoma diagnosis requires confirmation
• Testicular or ovarian tumor evaluation is needed
• Tumor classification is unclear
• Routine biopsy results are inconclusive
• Cancer subtype differentiation is required
• Tumor marker confirmation is necessary
• Oncology treatment planning depends on exact diagnosis

This test provides critical diagnostic clarity for accurate cancer management.

Preparation Before the Test

Preparation usually includes:

• Submission of FFPE tissue block or unstained slides
• Previous histopathology reports
• Relevant imaging and clinical records
• Proper tissue labeling and packaging
• Laboratory authorization documentation

No fasting or direct patient preparation is required.

Normal Reporting Time

The normal reporting time for the β-hCG IHC Test is usually 4–7 working days, depending on staining complexity and interpretation requirements.

Who Should Take This Test?

This test is recommended for:

• Patients with suspected germ cell tumors
• Individuals undergoing trophoblastic tumor evaluation
• Patients requiring advanced tumor classification
• Individuals with unclear biopsy diagnosis
• Oncology patients under specialist care
• Patients requiring expert immunohistochemistry confirmation

At Focus Diagnostics Hyderabad, advanced immunohistochemistry technology and expert oncopathology specialists ensure highly accurate β-hCG IHC reports for reliable diagnosis and personalized cancer treatment planning.